| h-SDA-2026-0416-0190 | [Archived Hypothesis] | 0.05 | 0.00 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| h-SDA-2026-0401-0001 | [Archived Hypothesis] | 0.05 | 0.00 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| h-test | [Archived Hypothesis] | 0.05 | 0.00 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| H-000001 | [Archived Hypothesis] | 0.05 | 0.00 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| SDA-2025-02-27-897 | [Archived Hypothesis] | 0.05 | 0.00 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| nlrp3-inflammasome-p | [Archived Hypothesis] | 0.05 | 0.50 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| h-000001 | [Archived Hypothesis] | 0.05 | 0.00 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| h-77e89f79 | [Archived Hypothesis] | 0.05 | 0.00 | | archived | 2026-04-17 | legacy-pre-pipeline-import-v1 |
| h-debate-414842a3f31 | Critical Evaluation of the Allen Brain SEA-AD MTG snRNA-seq Dataset | 0.00 | 0.55 | SEA | proposed | 2026-04-28 | |
| h-debate-a08d62eafe9 | Methodological Evaluation of the SEA-AD MTG Differential Expression Dataset | 0.00 | 0.55 | SEA | proposed | 2026-04-28 | |
| h-debate-0b981f1e439 | Methodological Vulnerabilities in the SEA-AD snRNA-seq Dataset | 0.00 | 0.55 | SEA | proposed | 2026-04-28 | |
| h-debate-427bfcb0c2d | Critical Evaluation of the Allen Brain SEA-AD Dataset Methodology | 0.00 | 0.55 | SEA | proposed | 2026-04-28 | |
| h-debate-21fb4d29b33 | Synthesis and Constructive Resolution Toward Methodological Reformation in Inter | 0.00 | 0.55 | | proposed | 2026-04-28 | |
| h-debate-95a74259aa1 | Statistical Underpowering and the Reproducibility Crisis in Mitochondrial Transf | 0.00 | 0.55 | | proposed | 2026-04-28 | |
| h-debate-cdd42c290bb | Resolving Mechanistic Heterogeneity Through Precision Medicine and Staged Interv | 0.00 | 0.55 | ALS | proposed | 2026-04-28 | |
| h-debate-fe7218bf407 | Advancing Beyond Traditional Druggability Through RNA-Guided Precision Therapeut | 0.00 | 0.55 | RNA | proposed | 2026-04-28 | |
| h-debate-89896f73e10 | Addressing Falsification Through Integrated Multi-Target Framework | 0.00 | 0.55 | TDP | proposed | 2026-04-28 | |
| h-debate-51ed53ada29 | Advancing Beyond Traditional Druggability Through RNA-Guided Precision Therapeut | 0.00 | 0.55 | RNA | proposed | 2026-04-28 | |
| h-debate-718bb32a48d | Targeting TDP-43 Phase Separation Through Selective RNA-Binding Modulation | 0.00 | 0.55 | TDP | proposed | 2026-04-28 | |
| h-debate-809970effb8 | Concrete Development Roadmap and Final Position | 0.00 | 0.55 | | proposed | 2026-04-28 | |
| h-debate-2cf8c8ca336 | Strategic Reframing and Targeted Innovation | 0.00 | 0.55 | CRISPR | proposed | 2026-04-28 | |
| h-debate-b9cea28255a | Convergent Multi-Modal CRISPR Architectures (Continued) | 0.00 | 0.55 | CRISPR | proposed | 2026-04-28 | |
| h-debate-8eee3d97b8e | Next-Generation CRISPR Innovations for Huntington's Disease | 0.00 | 0.55 | CRISPR | proposed | 2026-04-28 | |
| h-debate-b33a7b68ff9 | Novel CRISPR-based Therapies for Huntington's Disease: A Multi-Target Precision | 0.00 | 0.55 | CRISPR | proposed | 2026-04-28 | |
| h-debate-2ec23560a24 | Addressing Unfalsifiability with Precision | 0.00 | 0.55 | ATAC | proposed | 2026-04-28 | |
| h-debate-c6818b9e921 | Defending and Extending the Adaptive Decline Model | 0.00 | 0.55 | PMID | proposed | 2026-04-28 | |
| h-debate-e7caaa726ca | Astrocyte-Neuron Metabolic Coupling as the Master Plasticity Gatekeeper | 0.00 | 0.55 | | proposed | 2026-04-28 | |
| h-debate-4d2d3eb1dae | Astrocyte-Neuron Metabolic Coupling as the Master Plasticity Gatekeeper | 0.00 | 0.55 | | proposed | 2026-04-28 | |
| h-debate-829763a5efc | Microglia-mediated antigen presentation creates a peripheral sink for tau antibo | 0.00 | 0.55 | | proposed | 2026-04-28 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-debate-61c7a283cc0 | Endosomal escape is the critical intracellular bottleneck for propagation | 0.00 | 0.55 | | proposed | 2026-04-28 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-debate-267a7e805b7 | Exosome-mediated propagation is the dominant pathway for long-distance tau sprea | 0.00 | 0.55 | | proposed | 2026-04-28 | SDA-2026-04-04-gap-tau-prop-20260402003221 |
| h-debate-5d177c09e0a | The "Trans-Cellular Prion-Like Propagation of Transcriptional Memory" Model | 0.00 | 0.55 | SEA | proposed | 2026-04-28 | analysis-SEAAD-20260402 |
| h-debate-f72ec2606d1 | The "Selective Vulnerability through Metabolic Licensing" Model | 0.00 | 0.55 | SEA | proposed | 2026-04-28 | analysis-SEAAD-20260402 |
| h-debate-050a2e63993 | CD63-Targeted Exosome Cargo Selectivity | 0.00 | 0.55 | CD63 | proposed | 2026-04-28 | SDA-2026-04-02-gap-tau-prop-20260402003221 |
| h-debate-74c0c34e453 | Synaptic VDAC1-Mediated Mitochondrial Tau Trafficking | 0.00 | 0.55 | VDAC1 | proposed | 2026-04-28 | SDA-2026-04-02-gap-tau-prop-20260402003221 |
| h-debate-7fdb34e4612 | APOE-Mediated Tau Clearance Enhancement | 0.00 | 0.55 | APOE | proposed | 2026-04-28 | SDA-2026-04-02-gap-tau-prop-20260402003221 |
| h-debate-2bb456a643c | FYN-Mediated Extracellular Vesicle Release Inhibition | 0.00 | 0.55 | FYN | proposed | 2026-04-28 | SDA-2026-04-02-gap-tau-prop-20260402003221 |
| h-debate-1de42f4188f | GSK3β-Dependent Tau Phosphorylation Cycling Modulation | 0.00 | 0.55 | GSK3B | proposed | 2026-04-28 | SDA-2026-04-02-gap-tau-prop-20260402003221 |
| h-debate-2a00cc4f41c | Multi-Cell Type Aging Clock Synchronization | 0.00 | 0.55 | Multiple | proposed | 2026-04-28 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-debate-bd37eafbc00 | Astrocyte Metabolic Reprogramming Therapy | 0.00 | 0.55 | Multiple | proposed | 2026-04-28 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-debate-f3f40ca6614 | Neuronal MAPT-Vulnerability Stratified Therapy | 0.00 | 0.55 | MAPT | proposed | 2026-04-28 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-debate-7c931dcbc5d | Selective SYK Inhibition for Neuroprotective Microglia | 0.00 | 0.55 | SYK | proposed | 2026-04-28 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-debate-19532f799d5 | TIM-3 Checkpoint Modulation in Microglia | 0.00 | 0.55 | HAVCR2 | proposed | 2026-04-28 | SDA-2026-04-03-gap-seaad-v2-20260402032945 |
| h-debate-669d93190fe | NF-κB/β-Catenin Competitive Binding Modulation | 0.00 | 0.55 | | proposed | 2026-04-28 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-debate-6adbfa431d7 | Sepsis-Associated Encephalopathy Prevention via Early BBB Stabilization | 0.00 | 0.55 | | proposed | 2026-04-28 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-debate-b23031e2aee | Endocannabinoid-Mediated Tight Junction Stabilization | 0.00 | 0.55 | | proposed | 2026-04-28 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-debate-34efaec3c6a | Microglial-Endothelial Cross-Talk Disruption Therapy | 0.00 | 0.55 | | proposed | 2026-04-28 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-debate-90260a5f8a4 | Perivascular Cell Reprogramming via CREB Inhibition | 0.00 | 0.55 | CREB1 | proposed | 2026-04-28 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-debate-7974c5174f2 | Epigenetic Silencing of SPP1 in Disease-Associated Microglia | 0.00 | 0.55 | HDAC1 | proposed | 2026-04-28 | SDA-2026-04-15-gap-pubmed-20260406-062118-e3613755 |
| h-debate-fdeb17bb2db | Early Immune Challenge Tolerance Induction | 0.00 | 0.55 | IL10 | proposed | 2026-04-28 | SDA-2026-04-04-gap-20260404-microglial-priming-early-ad |